Clinical Trial
doi: 10.1212/01.wnl.0000197792.73656.c2.
PCV chemotherapy for recurrent glioblastoma
Affiliations
- PMID: 16505319
- DOI: 10.1212/01.wnl.0000197792.73656.c2
Item in Clipboard
Clinical Trial
PCV chemotherapy for recurrent glioblastoma
Neurology.
.
Abstract
The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.
Similar articles
-
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.Clin Cancer Res. 2000 Oct;6(10):3878-84. Clin Cancer Res. 2000. PMID: 11051233 Clinical Trial.
-
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.Cancer. 2004 Feb 15;100(4):807-13. doi: 10.1002/cncr.20042. Cancer. 2004. PMID: 14770438 Clinical Trial.
-
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.Oncol Rep. 2007 Jun;17(6):1359-64. Oncol Rep. 2007. PMID: 17487391
-
[A case of the immediate efficacy of chemotherapy in a female patient with a glioblastoma].Zh Vopr Neirokhir Im N N Burdenko. 1996 Oct-Dec;(4):39-41. Zh Vopr Neirokhir Im N N Burdenko. 1996. PMID: 9092255 Review. Russian. No abstract available.
-
How did lomustine become standard of care in recurrent glioblastoma?Cancer Treat Rev. 2020 Jul;87:102029. doi: 10.1016/j.ctrv.2020.102029. Epub 2020 May 4. Cancer Treat Rev. 2020. PMID: 32408220 Review.
Cited by
-
Nimodipine Used with Vincristine: Protects Schwann Cells and Neuronal Cells from Vincristine-Induced Cell Death but Increases Tumor Cell Susceptibility.Int J Mol Sci. 2024 Sep 27;25(19):10389. doi: 10.3390/ijms251910389. Int J Mol Sci. 2024. PMID: 39408743 Free PMC article.
-
PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma.Oncotarget. 2018 May 8;9(35):23923-23943. doi: 10.18632/oncotarget.25246. eCollection 2018 May 8. Oncotarget. 2018. PMID: 29844863 Free PMC article.
-
Impact of imaging measurements on response assessment in glioblastoma clinical trials.Neuro Oncol. 2014 Oct;16 Suppl 7(Suppl 7):vii24-35. doi: 10.1093/neuonc/nou286. Neuro Oncol. 2014. PMID: 25313236 Free PMC article.
-
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.PLoS One. 2018 Mar 2;13(3):e0193694. doi: 10.1371/journal.pone.0193694. eCollection 2018. PLoS One. 2018. PMID: 29499065 Free PMC article.
-
Nonsurgical treatment of recurrent glioblastoma.Curr Oncol. 2015 Aug;22(4):e273-81. doi: 10.3747/co.22.2436. Curr Oncol. 2015. PMID: 26300678 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
